for people ages 18 years and up (full criteria)
study started
estimated completion
Principal Investigator
by Sandip Patel, MD (ucsd)
Headshot of Sandip Patel
Sandip Patel



Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 single agent treatment and DSP107 in combination with atezolizumab in second line treatment of non small cell lung cancer

Official Title

Phase I/II Study of DSP107 in Subjects With Advanced Solid Tumors Including a Dose-escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination With Atezolizumab (Part 2)


This study will be the first time that DSP107 is administered to human subjects. The aim of the study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of DSP107 monotherapy and combination therapy in a two-part design. Part 1 will involve DSP107 monotherapy dose escalation in subjects with advanced solid tumors that are not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit. Additional dose finding cohorts will be enrolled to establish a safe dose of DSP107 when given in combination with atezolizumab. Part 2 will comprise a single expansion cohort consisting of two treatment arms in which subjects will be treated either with DSP107 monotherapy or DSP107 in combination with atezolizumab. This part of the study will enrol subjects with non small cell lung cancer who have progressed following first line treatment with PD-1 or PD-L1 targeting agents having previously achieved a best response of stable disease or better.


Advanced Solid Tumor, Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Atezolizumab, DSP107, DSP107 monotherapy


You can join if…

Open to people ages 18 years and up

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Subject must have measurable disease per RECIST version 1.1
  • Part 1:

o Histologically confirmed advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit or subject is intolerant or has refused available therapies

  • Part 2:
  • Histologically confirmed, inoperable non-small cell lung cancer (Stage 3b or Stage 4)
  • Squamous and non-squamous histologies are both acceptable
  • Wildtype for actionable oncogenic driver mutations
  • Received first line treatment including anti PD-1 or anti PD-L1 therapeutic agent ± chemotherapy and achieved a best response of stable disease measured after 12 weeks of treatment

You CAN'T join if...

  • Life expectancy of ≤ 3 months
  • Central nervous system (CNS) metastases
  • Life-threatening (grade 4) immune-mediated adverse event related to prior immunotherapy
  • Immune-mediated adverse reaction that required discontinuation of prior immunotherapy
  • Past or current history of autoimmune disease or immune deficiency
  • History of autoimmune hemolytic anemia or autoimmune thrombocytopenia
  • History of hematological malignancy
  • History of organ or stem cell transplantation
  • Clinically significant liver disease, including alcoholic hepatitis, cirrhosis, fatty liver disease and inherited liver disease
  • Previously treatment with CAR-T cells
  • Treatment with systemic immunosuppressive medication within 2 weeks prior to first dose of study treatment
  • Received live, attenuated vaccine within 4 weeks prior to first dose of study treatment
  • Treatment with systemic immunostimulatory agents within 4 weeks prior to first dose of study treatment
  • Treatment with atezolizumab, any CD47/SIRPα targeting agent or immune agonists (e.g., anti-CD137, anti-CD40, anti-OX40)
  • Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product
  • Clinically significant abnormal laboratory safety tests
  • Detection of anti DSP107 antibodies at screening
  • History of HIV infection or active Hepatitis B or C infection
  • Pregnant or breast feeding or planning to become pregnant while enrolled in the study
  • History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease


  • Moores Cancer Center, UCSD not yet accepting patients
    La Jolla California 92093 United States
  • University of Colorado Hospital, Anschutz Cancer Pavilion (ACP) accepting new patients
    Aurora Colorado 80045 United States

Lead Scientist at University of California Health

  • Sandip Patel, MD (ucsd)
    Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 44 research publications. Research interests: cancer immunotherapy · phase 1 clinical trials · cellular therapy · immunometabolism · microbiome · IDO · personalized medicine · precision medicine · CAR-T cell · NK cell · proteomics · immunotherapy


accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
Kahr Medical
Phase 1/2 research study
Study Type
Expecting 100 study participants
Last Updated